Core Viewpoint - China Resources Sanjiu (华润三九) reported its 2025 performance, showing a revenue increase and a modest rise in net profit [1] Financial Performance - The company achieved an operating revenue of 31.629 billion yuan, representing a year-on-year growth of 14.53% [1] - The net profit attributable to shareholders reached 3.422 billion yuan, with a year-on-year increase of 1.6% [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 昆藥集團截至2025年12月31日止年度的初步財務資料 於2026年2月6日，昆藥集團公佈其截至2025年12月31日止年度的未經審核初步 財務資料。 昆藥集團股份有限公司（「昆藥集團」）為一家於中華人民共和國註冊成立的公司。 昆藥集團的股份於上海證券交易所上市。截至本公告日期，昆藥集團由華潤醫藥 集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）透過其非全資附屬公 司華潤三九醫藥股份有限公司（「華潤三九」）持有約28.05 %的股權，並為本公司的 附屬公司。 股本 75,697.58 75,697.58 0.00 % 上市公司股東應佔每股淨資產 – 1 – （ 人民幣 ） 7.08 6.94 2.02 % 附註： (1) 報告期初的資料與根據適用法律及法規披露的去年年末 ...

Core Viewpoint - The company, China Resources Sanjiu (华润三九), reported its 2025 annual performance, highlighting a strategic focus on "innovation + brand" to navigate a complex market environment, aiming to solidify its position as an industry leader [1] Financial Performance - The company achieved total operating revenue of 31.629 billion yuan, representing a year-on-year increase of 14.53% [1] - The net profit attributable to shareholders of the listed company was 3.422 billion yuan, reflecting a year-on-year growth of 1.60% [1] Strategic Focus - The company is concentrating on core therapeutic areas and expanding its research and development pipeline to enhance innovation value [1] - It is also committed to optimizing its business layout and strengthening brand advantages to build a competitive edge across the entire industry chain [1] - The strategic goal is to become a leading enterprise in the industry [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) reported a total operating revenue of 31.629 billion yuan for the fiscal year 2025, representing a year-on-year increase of 14.53%. The net profit attributable to shareholders reached 3.422 billion yuan, reflecting a year-on-year growth of 1.60% [1] Group 1 - The company focused on core therapeutic areas and expanded its R&D pipeline from multiple dimensions [1] - The company emphasized enhancing brand advantages and continuously optimizing its business layout [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) reported a total revenue of 31.629 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 14.53%, and a net profit attributable to shareholders of 3.422 billion yuan, which is a 1.60% increase year-on-year [1] Group 1 - The company focuses on core therapeutic areas and expands its R&D pipeline from multiple dimensions to enhance innovation value [1] - The company strengthens its brand advantages and continuously optimizes its business layout [1]

Group 1: Industry Overview - The Chinese traditional medicine industry is experiencing a performance recovery, with several leading companies like Yiling and Jiangzhong releasing positive profit growth signals due to marketing reforms, product structure optimization, and cost improvements [1] - Policies such as "Opinions on Improving the Quality of Traditional Chinese Medicine" are creating market opportunities for compliant enterprises, while demographic trends like aging population and the consumption upgrade from Generation Z are driving demand [1] - The population aged 78 and above in China is projected to increase from 32-33 million to 360 million in 25 years, indicating a strong and sustained demand for conservative treatments for chronic diseases [1] Group 2: Company Performance - Tianshili's forecast for 2025 indicates a net profit of 1.105 billion yuan, representing a year-on-year increase of 15.68% [1] - In the first three quarters, Tianshili's pharmaceutical industrial revenue reached 5.709 billion yuan, maintaining stability, with a net profit of 984 million yuan, reflecting a year-on-year growth of 16.88% [2] - The cardiovascular/metabolism segment generated 3.186 billion yuan in revenue during the same period, showing a slight year-on-year growth of 1.16% [2] Group 3: Innovation and Strategic Development - After becoming a member of China Resources Sanjiu, Tianshili has successfully completed a hundred-day integration process, focusing on value, business, organizational, and spiritual restructuring [3] - Tianshili is positioned as the "innovation-driven" wing of the "one body, two wings" strategy, with 31 innovative drugs currently in the research pipeline, including nearly 20 products in late-stage clinical trials [3] - Analysts believe Tianshili's focus on three core disease areas and its rich R&D pipeline present opportunities for value reassessment, with expectations for stable growth in its main business as new products are approved and launched [3]

Core Viewpoint - The company reported a total operating revenue of 31.629 billion yuan for 2025, representing a year-on-year increase of 14.53%, and a net profit of 3.422 billion yuan, with a year-on-year growth of 1.60% [1] Group 1 - The company is facing challenges such as a decrease in the incidence of respiratory diseases like influenza and ongoing medical insurance cost control [1] - The company aims to maintain a strategic direction focused on "innovation + brand" dual-driven approach to navigate the complex market environment [1] - The company is concentrating on core therapeutic areas, expanding its research and development pipeline, and enhancing its brand advantages to solidify its competitive edge across the entire industry chain [1] Group 2 - The company is committed to optimizing its business layout and reinforcing its leading position in the industry, with a strategic goal of becoming a top player in the sector [1]

华润三九公告称，2025年营业总收入316.29亿元，同比增长14.53%；归属于上市公司股东的净利润 34.22亿元，同比增长1.60%。营业利润48.48亿元，同比增8.34%；利润总额48.60亿元，同比增5.81%。 扣非后归属于上市公司股东的净利润31.56亿元，同比增1.23%。2025年末总资产588.07亿元，较上年同 期增长46.72%，主要因并购天士力医药集团。此外，2025年6月实施2024年度权益分派，以资本公积金 每10股转增3股。 ...

股票代码：000999 股票简称：华润三九 公告编号：2026—003 华润三九医药股份有限公司 2. 公司于2025年6月实施完成2024年度权益分派方案，以资本公积金向全体股东每10股转 增3股，2025年末归属于上市公司股东的每股净资产以转增后股本计算填列。 3. 公司2025年末总资产5,880,727.61万元，较上年同期增长46.72%，主要是本期并购天 士力医药集团股份有限公司导致。 二、经营业绩和财务状况情况说明 2025 年，面对流感等呼吸道疾病发病率同比降低、医保控费持续等因素影 响，公司锚定战略航向，坚持"创新+品牌"双轮驱动，在复杂市场环境中稳健 前行。公司聚焦核心治疗领域，多维度扩充研发管线，深挖创新价值；厚植品牌 优势，不断优化业务布局，锻造全产业链竞争优势，巩固行业领军地位，朝着"争 做行业头部企业"的战略目标坚实迈进。报告期内，公司实现营业总收入 316.29 亿元，同比增长 14.53%；实现归属于上市公司股东的净利润 34.22 亿元，同比 增长 1.60%。 2025 年度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大 ...

"十五五"规划下，医药领域的国家队企业备受资本市场关注。天士力2025年加入华润体系后成为华润三 九"一体两翼"战略中的"一翼"，首年融合业绩超出市场预期。公司近日发布2025年全年业绩预告称，预 计实现归母净利润11.05亿元，同比增加15.68%。 据公司此前披露，在百日融合期内公司与华润三九协同赋能，在营销领域整合线上线下渠道资源，创新 医药零售新模式。在营销领域积极与华润进行融合赋能，并加强与华润医商"新产品"合作，建立新品目 标终端开发协同机制。在渠道拓展方面，与华润三九健康消费品（CHC）业务开展了充分协同。借助 华润三九药品零售连锁（KA）平台，公司与头部连锁药店深化战略合作关系，并选取代表性产品入驻 三九旗舰店，与华润三九在产品打造、数据共享等各方面开展了深入合作。 信达证券近期研报指出，华润三九是国内健康消费品领域的龙头，具备行业领先的渠道资源和品牌能 力，作为华润系央企，同时具备富有远见的战略规划和市场化的经营思路，目前双方融合顺利推进，有 望给天士力带来积极变革。申万宏源证券的研报也指出，期待华润三九将借助其在管理、渠道、产业方 面的资源，为公司进一步赋能，促进协同效应，提升天士力的竞争 ...